Disease distribution and latency curves for SRS19-6–induced myeloid and lymphoid leukemias. Disease distributions of SRS19-6–injected (A) Cebpa^+/+ (+/+; n = 19), (B) Cebpa^+/BRM2 (+/BRM2; n = 17), and (C) Cebpa^BRM2/BRM2 (BRM2/BRM2; n = 32) mice. Mice were either diagnosed with T-cell ALL, B-cell ALL, myeloid leukemia, or mixed (T-ALL/myeloid leukemia, B-ALL/myeloid leukemia, or T-ALL/B-ALL). (D) Kaplan-Meier survival curves for myeloid leukemias of SRS19-6–injected mice of the following genotypes: Cebpa^+/+ (+/+; n = 8), Cebpa^+/BRM2 (+/BRM2; n = 11), and Cebpa^BRM2/BRM2 (BRM2/BRM2; n = 22). (E) Kaplan-Meier survival curves for lymphoid leukemias (T-cell, B-cell) of SRS19-6–injected Cebpa^+/+ (+/+; n = 11), Cebpa^+/BRM2 (+/BRM2; n = 5), and Cebpa^BRM2/BRM2 (BRM2/BRM2; n = 10). Statistical significance was determined as in Figure 1.